Clinical trials: Mild Hypertension
Mild Hypertension, Air Pollution Exposure
Reducing Air Pollution to Lower Blood Pressure
Fine particulate matter <2.5 μm (PM2.5) air pollution is the fifth leading risk factor for global mortality. Mitigating the clinically significant blood pressure (BP) elevation from air pollution by reducing PM2.5 exposure will…
- Trial name
- AIR PRESSURE (NCT04908917)
- Testing
- Portable Air Cleaner with a HEPA Filter, Portable Air Cleaner without a HEPA Filter
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Osteopenia, Arterial Hypertension
Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women
This study evaluates the effect of moxonidine versus bisoprolol on collagen type 1 C-telopeptide in postmenopausal female patients with arterial hypertension and osteopenia.
- Trial name
- COMPASS (NCT02355821)
- Testing
- Moxonidine, Bisoprolol
- Where
- Russia
- Volunteers
- 114 people
- Sponsor
- National Research Center for Preventive Medicine
Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).
- Conditions
- Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF, HFpEF
- Trial name
- NCT07147114
- Testing
- Combination therapy, Monotherapy
- Where
- 15 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Gachon University Gil Medical Center
Hypertension, Impaired Glucose Tolerance
Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate…
- Trial name
- NCT00847899
- Testing
- AR9281
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Arete Therapeutics
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Hypertension, Mild Cognitive Impairment
Retina Microvascular Remodeling and Cognitive Function In Hypertension
This study aims to determine the relationships between retina micro-vascular remodeling and cognitive function in hypertensive patients.
- Trial name
- EYEBRAIN (NCT02701855)
- Testing
- Cognitive tests, Blood test, Brain and aorta RMI
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Institute of Cardiometabolism and Nutrition, France
Hypertension
The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care
The objective of this study is to evaluate the safety and efficacy of Limitless, in combination with a low-carbohydrate diet, after 30 days of supplementation in an adult population.
- Trial name
- NCT05298410
- Testing
- Limitless
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Limitless Research Inc.
Open-angle Glaucoma, Cataract
Efficacy and Safety of Trabecular Meshwork Microstent Drainage System ( MicroCOGO )
It is a prospective, multicenter, randomized, open label, parallel controlled, superiority clinical trial that evaluate efficacy and safety of Trabecular Meshwork Microstent Drainage System in Reducing Intraocular Pressure in…
- Trial name
- MicroCOGO (NCT06741774)
- Testing
- Trabecular Meshwork Microstent Drainage System, phacoemulsification
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Healthguard Biomed
Hypertension
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
The purpose of this study is compare treatment with valsartan with the possible addition of a diuretic, hydrochlorothiazide, on high blood pressure with the drug amlodipine with the possible addition of a diuretic…
- Trial name
- NCT00171054
- Testing
- Valsartan 320 mg, Amlodipine 10 mg, Hydrochlorothiazide
- Where
- Switzerland
- Volunteers
- 125 people
- Sponsor
- Novartis
Essential Hypertension
Essential Hypertension
The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.
- Trial name
- REDUCE-1 (NCT01264692)
- Testing
- ACT-280778, Amlodipine
- Where
- 18 sites in Israel, Serbia
- Volunteers
- 196 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma
The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open angle-glaucoma (OAG).
- Trial name
- NCT01670266
- Testing
- ONO-9054
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ono Pharma USA Inc
Essential,Hypertension
Fimasartan Achieving SBP Target (FAST) Study
The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to Valsartan and Olmesartan(reference group) in patients with mild to moderate essential hypertension.
- Trial name
- FAST (NCT02495324)
- Testing
- Fimasartan, Valsartan, Olmesartan medoxomil
- Where
- 8 sites in South Korea
- Volunteers
- 369 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Cognitive Decline
Remote Monitoring and Virtual Collaborative Care For Hypertension Control To Prevent Cognitive Decline
This purpose of this study is to examine an aggressive method of blood pressure control that involves home blood pressure monitoring and management of medications by a team of clinical pharmacists in coordination with a primary…
- Trial name
- vCCC (NCT04585880)
- Testing
- Virtual Collaborative Care Clinic
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Hypertension
AVE7688 in Patients With Mild to Moderate Blood Pressure
The primary objective is to assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from baseline in trough diastolic blood pressure at the end of week 12.
- Trial name
- RAVEL-1 (NCT00284128)
- Testing
- AVE7688, Losartan-potassium
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 1,940 people
- Sponsor
- Sanofi
Hypertension
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
This CLAZ696B11302 study is composed of two parts; the Core part including double-blind period, and the open-label extension (OLE) part which is an open-label extension of the Core part.
- Trial name
- NCT06236061
- Testing
- LCZ, LCZ/AML 200 mg/2.5 mg, LCZ/AML 200 mg/5 mg
- Where
- 43 sites in Japan
- Volunteers
- 718 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition.
- Trial name
- ASSERTIVE (NCT00865020)
- Testing
- Aliskiren, Telmisartan
- Where
- 16 sites in Brazil, Canada and 14 more
- Volunteers
- 822 people
- Sponsor
- Novartis
Hypertension,Essential
Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects.
- Trial name
- NCT06501586
- Testing
- SGB-3908
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.
Essential Hypertension
Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
This is an 8-week, randomized, double-blind Phase 3, multicentre study to determine the optimal dose of AZM and AML in combination therapy and to compare efficacy and tolerability of the combined therapy to each of the…
- Trial name
- NCT05385770
- Testing
- AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg
- Where
- South Korea
- Volunteers
- 890 people
- Sponsor
- Celltrion
Essential Hypertension
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-Folic Acid Tablets on reduction of blood pressure and plasma total homocysteine.
- Trial name
- NCT01956786
- Testing
- Amlodipine-FA tablet,low dose group, Amlodipine-FA tablet,high dose group, Amlodipine
- Where
- 3 sites in China
- Volunteers
- 540 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Essential Hypertension
Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension
This study will evaluate the efficacy and safety of weak extremely low frequency electromagnetic fields (ELF-EMF) in mild and moderate essential hypertension.
- Trial name
- NCT00709930
- Testing
- Magnetic field generator
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kyoto University